Moberg Pharma AB (publ)

MOB · Nasdaq Stockholm · Healthcare

11.14SEK +1.3%last day

Price as of 2 October 2026

The price over the past year, with dividends: +26.0%

Performance

1 month

+0.2%

1 year

+26.0%

3 years, per year

+20.3%

5 years, per year

−22.0%

Largest fall, 3 years

−91.9%

Below the peak now

−97.6%

Volatility, 1 year

52.1%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.8

Dividend yield

0.0%

Return on equity

−3.3%

Net margin

−129.0%

Market value

52 m USD

Quality, value and trend

Where Moberg Pharma stands against every Nordic stock today. 100 is best.

Quality83

Profitability and a sound balance sheet over time. Better than 83% of Nordic stocks.

Value32

The price measured against earnings, assets and cash flow. Better than 32% of Nordic stocks.

Trend81

The price development over the past year. Better than 81% of Nordic stocks.

Combined80

Quality, value and trend together. Better than 80% of Nordic stocks.

About Moberg Pharma

Moberg Pharma AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 5 employees.

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis